Multiple Sclerosis
Sanofi’s Tolebrutinib Shows Mixed Results in Multiple Sclerosis Trials
Sanofi, Tolebrutinib, Multiple Sclerosis, BTK Inhibitor, Clinical Trials
Biogen Faces Lawsuit Over Alleged Kickback Scheme to Block Generic Competition for Multiple Sclerosis Drug Tecfidera
Biogen, kickback scheme, Tecfidera, generics, multiple sclerosis, PBM, lawsuit
Progentos Secures $65 Million for Groundbreaking Remyelination Therapy in Multiple Sclerosis Treatment
Progentos, funding, remyelination therapy, multiple sclerosis, MS treatment, clinical trials, neurodegenerative diseases, nervous system repair, biotechnology.
Roche’s Ocrevus Demonstrates Near-Complete Reduction of Relapse and Lesions in Multiple Sclerosis
Ocrevus, Roche, Multiple Sclerosis (MS), Relapse reduction, Lesion reduction, Clinical and MRI measures
“Continuum Biologics’ PIPE-791 Advances with Johnson & Johnson Partnership in Initial Public Offering (IPO)”
Continuum Biologics, PIPE-791, Johnson & Johnson partnership, Initial Public Offering (IPO), Multiple sclerosis, Demyelinating diseases, Neuroinflammation, LPAR1 antagonist, Lysophosphatidic acid receptor Edg-2 antagonist
Contineum Launches IPO Campaign to Accelerate Multiple Sclerosis Pipeline
Contineum Therapeutics, Initial Public Offering (IPO), Johnson & Johnson (J&J) Backed, Multiple Sclerosis (MS) Pipeline, Phase II Trial, PIPE-307
Merck KGaA Abandons Evobrutinib Development, Emphasizes Deal-Focused Pipeline Strategy
Merck KGaA, Evobrutinib, BTK Inhibitor, Deal-driven Pipeline Strategy, Discontinuation of Development, Failed Phase 3 Trials, Multiple Sclerosis (MS) Treatment